Is it game over for pharma flop Indivior after 75% crash?

What’s gone wrong at Indivior plc (LON:INDV) and what would I do now? Roland Head gives his verdict.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 250 pharmaceutical firm Indivior (LSE: INDV) fell by more than 75% on Wednesday morning. The stock’s collapse was triggered by news that the company has been charged with fraud offences by the US Department of Justice.

The company warned that while it disputes the allegations, a verdict against it could have “a material adverse effect on the Company and its financial position”.

Here I’m taking a fresh look at this firm, which specialises in treatment for opioid addiction. Would I buy, sell or hold the stock after today’s news?

What are the charges?

The Department of Justice has charged Indivior with 28 felony counts, most of which are mail or wire fraud. These are broad charges, but according to the company, the DoJ is making two main claims.

The first claim is that Indivior encouraged doctors to prescribe Suboxone “to too many people or in too high doses” in order to boost sales.

The second claim is that the firm “misled doctors and patients” when it claimed its Suboxone Film product was safer than tablets and less likely to be abused or taken accidentally by children.

The US authorities are suggesting that the real motive for the introduction of Suboxone Film in 2007 was to use patent laws to prevent generic alternatives becoming available — something that has been a major focus for Indivior in recent years.

Will the company settle?

Indivior believes that “the allegations are unsupported by the facts and the law”. Most of the events involved are said to date from before the firm was spun out of Reckitt Benckiser in 2014.

However, the company says it has co-operated with the DoJ “for several years” and “made numerous attempts to reach a settlement”.

As the DoJ has now gone ahead and charged Indivior, I assume that a settlement is unlikely, if not impossible.

What should investors do now?

The firm has long looked speculative to me. For years, it’s been clear that profits were dependent on its ability to prevent generic rivals coming to market.

In February, management appeared ready to admit defeat, when the firm launched its own generic version of Suboxone Film. I covered this story here and suggested that revenue could fall by as much as 80% in 2019.

At that time, I didn’t know about the DoJ allegations. Even so, my verdict was that “buying the shares at current levels is little more than a gamble”.

Indivior shares have fallen even further since then, so is the stock worth a punt?

I wouldn’t touch it

Press reports I’ve seen today suggest the DoJ may be hoping for a fine of about $3bn. In my view, that would probably put Indivior out of business, leaving shareholders with nothing.

Even if the company manages to clear its name in court or secures a more affordable fine, the future looks highly uncertain to me.

I don’t see any way that outside investors can work out a meaningful valuation for this business. Nor can I see any way of predicting what’s likely to happen next.

In my view, this is a stock to avoid at all costs. If I was a shareholder, I’d accept defeat and sell, so that I could be sure of recovering some cash.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »